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Although structural and functional changes of resistance
arteries have been proposed to participate in arterial
hypertension (HTA) outcome, not all therapies may correct
these alterations, even if they normalize the blood pressure
(BP). The aim of this study was to investigate the mechanisms
of the protection afforded by the angiotensin receptor
antagonist losartan in resistance arteries from patients with
essential HTA. In all, 22 untreated hypertensive patients were
randomized to receive losartan or amlodipine for 1 year and
the morphological characteristics of resistance vessels from
subcutaneous biopsies were evaluated. Protein expression of
connective tissue growth factor (CTGF), transforming growth
factor b (TGF-b), and collagens III and IV was detected by
immunohistochemistry. In comparison with normotensive
subjects, resistance arteries from hypertensive patients
showed a significant media:lumen (M/L) ratio increment and
a higher protein expression of CTGF, TGF-b, and collagens.
After 1 year of treatment, both losartan and amlodipine
similarly controlled BP. However, M/L only decreased
in patients under losartan treatment, whereas in the
amlodipine-treated group this ratio continued to increase
significantly. The administration of losartan prevented
significant increments in CTGF, TGF-b, and collagens in
resistance arteries. By contrast, amlodipine-treated patients
showed a higher vascular CTGF, TGF-b, and collagen IV
staining than before treatment. Our results show that the
administration of losartan, but not amlodipine, to
hypertensive patients improves structural abnormalities and
prevents the production of CTGF and TGF-b in small arteries,
despite similar BP lowering. These data may explain the
molecular mechanisms of the better vascular protection
afforded by drugs interfering with the renin–angiotensin system.
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The kidney has an important dual role in hypertension
(HTA), both contributing to the increase in systemic
blood pressure (BP) and being damaged by its long-term
consequences.1 The increased peripheral resistance, the
hallmark of high BP, seems to be due to ‘remodeling’ of the
resistance arteries (o350 mm in diameter), characterized by
an increment in the media:lumen (M/L) ratio (reviewed in
Intengan and Schiffrin,2 and Mulvany3). The mechanisms
underlying this process are not completely elucidated,
although it has been suggested that changes in the expression
of extracellular matrix (ECM) may have a key role. An
increment in the deposition of collagens, the main compo-
nents of the ECM, has been shown in mesenteric resistance
arteries of hypertensive rats and in subcutaneous small
arteries of patients with mild essential HTA.2,4 In the kidney,
the vascular defect seems to reside in the preglomerular
resistance arterioles. Morphometric studies have demon-
strated a significant reduction of afferent arteriolar luminal
diameter in spontaneously hypertensive rats (SHR) com-
pared with normotensive Wistar–Kyoto rats.3 Also, the M/L
and wall thickness of the arcuate and interlobular arteries
were significantly greater in SHR than in Wistar–Kyoto rats.5
These structural alterations of resistance arteries,
described at the earliest stages in HTA,6 may participate
not only in the genesis of the hypertensive disease but also in
its complications.7 More recently, Rizzoni et al.8 have
demonstrated that vascular changes of subcutaneous small
arteries predict cardiovascular events in high-risk patient
populations, indicating an important direct role for the
microcirculation in the development of heart disease, stroke,
and renal disease. However, in spite of the available
antihypertensive agents, the number of patients with HTA
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reaching end-stage renal failure is increasing all over the
world and constitutes the second cause of entering dialysis
program after diabetic nephropathy. Therefore, we need
drugs that, besides an adequate control of BP, provide organ
protection. In this sense, normalization of resistance artery
structure should be regarded as an important target for
therapeutic interventions. Drugs interfering with the reni-
n–angiotensin system (RAS) have proved effective in reducing
not only BP but also structural alterations in resistance
arteries in both SHR and humans.9–13 It has been demon-
strated that the administration of the angiotensin type 1
(AT1) receptor antagonist losartan to SHR, even at doses that
mildly reduced BP, decreases the increased media width and
M/L in small arteries in several vascular beds such as
coronary, renal, mesenteric, and femoral.14 In essential hyper-
tensive patients, losartan improved structural abnormalities
and normalized the endothelial function of subcutaneous
small arteries, whereas a b-blocker had no effect.15 In the
recently published Losartan Intervention For End Point
Reduction in Hypertension Trial, losartan has shown to be
clinically superior to an atenolol-based therapy in reducing
cardiovascular morbidity and mortality despite comparable
BP lowering.16 Taken together, these data suggest that the
superiority of losartan treatment could not be attributed to
differences in BP although the mechanisms implicated in
these processes have not been fully identified.
Angiotensin II (Ang II), the main peptide of the RAS,
regulates cell growth and increases the production of ECM
through its AT1 receptors.17 In several cell types, including
vascular smooth muscle cells (VSMC), Ang II-induced ECM
production is mainly mediated by transforming growth
factor b (TGF-b),17,18 long considered the most important
regulator of ECM. We have recently described a novel
mediator of Ang II-induced vascular fibrosis: the connective
tissue growth factor (CTGF).19 CTGF participates in fibrotic
processes, including skin disorders, tumor development, and
renal and heart diseases.20 We have reported that Ang II-
induced hypertension increases aortic CTGF production and
vascular fibrosis via the activation of its AT1 receptor.19
Therefore, the aim of this study was to investigate the
molecular mechanisms of the protection afforded by losartan
in resistance arteries from untreated patients with recently
diagnosed essential HTA. To do that, small arteries were
taken from biopsies of subcutaneous fat that can be obtained
by a minimally invasive technique, and the expression of the
profibrogenic cytokines TGF-b and CTGF was assessed.
RESULTS
We have studied 22 hypertensive patients that had never
received any antihypertensive drugs. Both men and women
were recruited, although only women of non-child-bearing
potential age were included. Baseline clinical characteristics
of the studied subjects are shown in Table 1.
The administration of losartan (average dose of 7777 mg/
day) or amlodipine (average dose of 6.770.7 mg/day)
throughout 1 year demonstrated a similar BP control in
both groups, without significant differences between diastolic
and systolic BP achieved by losartan- and amlodipine-treated
patients at the end of the study (Figure 1). To achieve the
required BP values, addition of hydrochlorothiazide was
needed in seven patients receiving losartan (15.772.2 mg/day
for 8.771.0 months) and one patient receiving amlodipine
(23.8 mg/day for 10 months). None of the patients needed
the addition of doxazosin.
Small artery structure
The morphology of subcutaneous small arteries was studied
by the orcein Van Gieson stain that highlights the elastic
fibers and the collagen, permitting the distinction between
small and large arteries and veins as illustrated in Figure 2. In
relation to normotensive subjects, patients showed a reduced
lumen and increased M/L in resistance vessels, without
changes either in the media width or in the media cross-
sectional area (Table 2). At this time, although patients were
blindly assigned to receive losartan or amlodipine, a
significant increased M/L was found in those randomized
to losartan with respect to those randomized to amlodipine
(Table 2).
After 1 year of treatment, M/L decreased in patients
receiving losartan-based therapy, whereas in the amlodipine-
based group this ratio significantly increased in spite of the
Table 1 | Clinical characteristics of normotensive subjects and
hypertensive patients before treatment
Hypertensive subjects
Normotensive
subjects Losartan Amlodipine
Sex (male/female) 3/6 7/4 7/4
Age (years) 5073 5173 4475
Hypertension history (years) — 2.370.8 2.370.6
Systolic BP (mmHg) 12273 14573* 14473*
Diastolic BP (mmHg) 7772 9472* 9172*
Current smokers (y/n) 3/6 2/9 3/8
Serum creatinine (mg/dl) 0.970.1 0.970.2 1.070.2
Fasting glucose (mg/dl) 89710 96712 94710
Weight (kg) 72.878.1 71.773.1 81.072.7
Body Mass Index (kg/m2) 23.771.2 26.470.6* 29.170.8*
Data are mean7s.e.m. BP, blood pressure. *Po0.05 vs normotensive subjects.
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Figure 1 | (a) Systolic and (b) diastolic BP of hypertensive patients
treated with losartan or amlodipine during 1 year. Data are
mean7s.e.m., n¼ 8–11. *Po0.05 and **Po0.01 vs before treatment
(time 0).
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treatment (Table 2). Although patients treated with losartan
who required hydrochlorothiazide tended to have higher M/L
than patients who did not require it (82711 vs 63715%,
P¼NS), the reduction in the M/L observed in both sub-
groups was similar (13.078.4 vs 12.879.9%, P¼NS). At
the end of the study, the effect displayed by losartan in
monotherapy was significantly different from that displayed
by amlodipine alone (12.879.9 vs 20.376.2%, Po0.05).
Although, in our study, the imbalance in the number of
men and women did not reach statistical significance either in
each group or between groups, we also evaluated separately the
results from male and female normotensive and hypertensive
subjects. We did not find any significant difference between
men and women in the same group (Figure 3a). At the end of
the study, the significant different effect of losartan-based
therapy on M/L in comparison to amlodipine was maintained
within men and women (Figure 3b).
Vascular composition of small arteries
By immunohistochemistry, the expression of CTGF, TGF-b,
collagen III, and collagen IV was increased in the small
arteries from hypertensive patients in comparison with
normotensive subjects (Figures 4a–d). In the latter, the
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Figure 2 | (a, b) Morphological studies of resistance arteries and
(c, d) veins from subcutaneous fat biopsies from hypertensive
patients. No differences can be observed between (a) arteries and
(c) veins stained by Masson’s trichrome. (b) By Orcein Van Gieson
staining, small arteries present a well-defined internal elastic lamina.
The media consists of smooth muscle cells and the adventitia,
relatively thin, is formed by fibrous tissue. (d, e) By contrast, small
veins present irregular configuration of elastic fibers interspersed
with collagen fibers and smooth muscle cells. There is no distinct
internal or external lamina. Valves can extend into the lumen. Original
magnification (a, b, e)  400; (c, d) 200.
Table 2 | Morphologic characteristics of small arteries from normotensive subjects and patients before and after
antihypertensive treatment
Hypertensive subjects
Losartan Amlodipine
Normotensives Before After Before After
External diameter (mm) 81714 6078 4277z 7479 4273z
Lumen (mm) 49710 2675* 2073 3776 1972z
Media width (mm) 1572 1672 1172z 1872 1271z
Media:lumen ratio (%) 3875 7378* 6275z 5175*,w 7175z
MCSA (mm2) 392571464 28387713 13787503z 432371249 11517152z
Data are mean7s.e.m., *Po0.05 vs normotensives, wPo0.05 vs losartan group before treatment, zPo0.05 vs the same group before treatment. MCSA, media cross-sectional
area.
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Figure 3 | (a) M/L of resistance arteries from normotensive and
hypertensive males and females before and after losartan
and amlodipine administration. Data are mean7s.e.m.,
n¼ 4–7.*Po0.05 vs normotensives of the same sex. (b) Change in M/L
with respect basal conditions. Data are mean7s.e.m., n¼ 4–7.
*Po0.05 between treatments at the end of the study.
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staining of CTGF was present in the endothelial cell layer
(Figure 5a), while in patients before treatment positive CTGF
stain was also located in the media and adventitia (Figures 5b
and c). TGF-b was mainly found in the media layer in both
normotensive subjects and patients (Figures 6a–c).
The administration of losartan to hypertensive patients
for 1 year did not change significantly the CTGF and
TGF-b immunoreactivity in resistance arteries, although
it decreased the staining of both collagens III and IV
(Figures 5–7). By contrast, small arteries from amlodipine-
treated patients showed a higher labeling index for CTGF,
TGF-b, and collagen IV than before the initiation of the
treatment (Figures 5–7). Only collagen III decreased after the
treatment with amlodipine, although without statistical
significance (Figure 7a). At the end of the study, losartan-
treated patients had a marked decreased production of CTGF
and collagen IV when compared to amlodipine-treated group
(Figures 5 and 7b).
Expression of endothelin-1 in small arteries
In order to investigate other modulators of collagen
synthesis, the expression of endothelin-1 (ET-1), also
implicated in vascular pathophysiology, was examined.
Neither before nor after treatment we were able to find any
significant difference in the ET-1 expression of small arteries
between normotensive and hypertensive subjects. However,
the production of ET-1 tended to be higher in small arteries
from the amlodipine group both before and after treatments
(normotensive: 7.772.0 labeling index; losartan: 7.873.3
before and 6.470.9 after; amlodipine: 9.571.6 before and
10.471.9 after; P¼NS).
Correlations between profibrogenic factors
After 1 year of antihypertensive therapy, the expression of
CTGF significantly correlated with the levels of TGF-b
(r¼ 0.569, P¼ 0.011) and ET-1 (r¼ 0.617, P¼ 0.005) before
treatment. CTGF expression also correlated with values of
TGF-b (r¼ 0.501, P¼ 0.019) and collagen IV (r¼ 0.762,
Po0.001) at the end of the study.
DISCUSSION
The possible regression of resistance artery alterations is an
appealing goal of antihypertensive treatment. Thus, we have
investigated the potential mechanisms participating in this
reversibility. An important novel finding is that the admin-
istration of the AT1 receptor antagonist losartan, but not
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Figure 4 | Baseline expression of (a) CTGF, (b) TGF-b, (c) collagen
III and (d) collagen IV protein expression in resistance arteries
from normotensive and hypertensive subjects. Data are
mean7s.e.m., n¼ 8–11. *Po0.05 vs normotensive group.
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Figure 5 | Localization by immunohistochemistry of CTGF
protein in resistance arteries of (a) normotensive subjects
and (b, d) hypertensive patients before and after losartan and
(c, e) amlodipine administration. Brown positive CTGF staining was
found in the intima (arrow), media (arrowhead), and adventitia (open
arrow) (Original magnification: 400). (f) Effect of antihypertensive
treatment on CTGF expression in resistance arteries. Data are
mean7s.e.m., n¼ 8–11. *Po0.05 vs before treatment. #Po0.05
between treatments at the end of the study.
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amlodipine, to mild hypertensive patients prevented the
production of CTGF, TGF-b, and collagens III and IV, and
simultaneously resulted in regression of M/L. The control of
BP was good in both treated groups. Confirming previous
studies,21,22 amlodipine seemed to be more effective than
losartan in the control of BP since the number of patients
randomized to receive amlodipine than needed for other
antihypertensive drugs was significantly less than those
allocated to losartan. However, patients allocated to receive
losartan had significantly higher M/L than those allocated to
receive amlodipine. Thus, our results could confirm that high-
risk patients often need multiple drugs to achieve BP goal. In
any case, the different effect on vascular remodeling observed
between losartan and amlodipine, despite comparable BP
reduction, further suggests that the blockade of the RAS affords
an additional protective effect beyond BP control.
Most of the studies on the remodeling of small arteries
have been carried out by dissecting the vessels (reviewed in
Bund and Lee23 and Schiffrin et al.24). In another established
procedure, considered to provide more precise measure-
ments,23,24 vessels are fixed in situ under pressure. Although
certain limitations could appear in this last technique,24 fixed
tissues seemed more appropriate to us for determining the
expression of fibrogenic factors and matrix proteins, since
vascular structure can be studied following histological
preparation. Of note, the diameter of the arteries measured
in our study was smaller (60–80 mm) than that previously
reported by several authors (4200 mm).11–13,25,26 Although
probably our subcutaneous small arteries were not free
to change shape due to the surrounding connective tissue,
we cannot discard that the small arteries obtained came from
the same levels of the vascular tree as those reported in
previous papers.
In our study, we have observed significant differences in
the size of the arteries from patients assigned to losartan and
those to amlodipine, probably due to sampling bias. We
focused our attention in the M/L, considered to be a valid
and highly reproducible morphological parameter to be
compared within and between subjects because it is
independent from the dimensions of the vessels.2,3,23,24 In
our study, as in the previous ones, arteries from hypertensive
patients presented an increased M/L in comparison to
normotensive subjects that significantly decreased after 1
year of losartan treatment. In recent years, several studies
have demonstrated an almost complete normalization of
structural alterations in human subcutaneous resistance
arteries after different antihypertensive therapies, including
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Figure 6 | Localization by immunohistochemistry of TGF-b
protein in resistance arteries of (a) normotensive subjects and
(b, d) hypertensive patients before and after losartan and
(c, e) amlodipine administration. Both in normotensive subjects
and patients, brown-positive TGF-b staining was mainly found in the
media layer (arrowheads) (Original magnification: 400). (f) Effect of
losartan and amlodipine treatment in TGF-b expression in resistance
arteries. Data are mean7s.e.m., n¼ 8–11. *Po0.05 vs before
treatment.
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Figure 7 | Effect of losartan and amlodipine treatment in (a)
collagen III and (b) collagen IV expression in resistance arteries
from hypertensive patients. Data are mean7s.e.m., n¼ 8–11.
*Po0.05 vs before treatment. #Po0.05 between treatments at the
end of the study.
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those with losartan.12,13,15,25 By contrast, others and we could
only observe a significantly lower M/L after the administra-
tion of antihypertensive drugs, but the ratio remained
significantly higher than that in normotensive subjects.9,11,26
It is possible that complete normalization of vascular
structure after prolonged antihypertensive treatment can be
observed only when cardiovascular structural changes are not
particularly advanced. In our study, some hypertensive
patients showed left ventricular hypertrophy, whereas in
previous studies hypertensive patients did not show any
evidence of target organ damage at baseline.12,13,15,25 It is also
possible that even longer treatment duration could be
required in order to achieve a complete reversal of structural
changes in resistance vessels. In this sense, Schiffrin et al.27
have demonstrated a progressive improvement in the structure
of resistance arteries of hypertensive patients after 2 years of
treatment with an angiotensin-converting enzyme inhibitor.
The limitations that resulted from the difficulties inherent in
the recruitment of subjects for an invasive study such as this
one (i.e. inability to investigate large numbers of subjects or on
several occasions) did not allow us to make conclusions about
the existence of limits in the reduction of M/L.
The main finding of our study is that the structural
abnormalities displayed by resistance arteries from hyperten-
sive patients coincided with an increment in the expression of
the profibrogenic factors CTGF and TGF-b and the matrix
proteins collagen III and IV in comparison to normotensive
subjects. The administration of losartan, but not amlodipine,
prevented increments in CTGF, TGF-b, and collagens and
improved morphological lesions. It has been demonstrated
that cyclic mechanical stretch stimulation induces an
increment in the expression of CTGF, which can induce the
production of ECM proteins, mainly collagens and fibro-
nectin.20 Thus, increasing evidence from in vivo and in vitro
models suggests that CTGF may represent a downstream
effector molecule of the profibrotic activities of TGF-b.19,20
In this paper, the significant correlation between CTGF and
TGF-b expression further supports this pathogenic mechan-
ism in subcutaneous small arteries from hypertensive
patients. An unexpected result was that hypertensive patients
randomized to losartan treatment showed less baseline CTGF
and TGF-b protein expression than patients on amlodipine,
although more severe morphological lesions. Several studies,
including those from our laboratory, have reported that
different cell types from hypertensive strains show biosyn-
thetic and growth abnormalities.28–31 In this sense, VSMC
from hypertensive rats showed a higher affinity and number
of TGF-b receptors than did cells from normotensive rats,
and this difference seemed to contribute to the exaggerated
growth of SHR-derived VSMC.31 Thus, it is possible that our
results would suggest a higher level of sensitivity to
profibrogenic factors by cells from hypertensive patients,
rather than an increase in these factors.
In any case, after 1 year of equally effective antihyper-
tensive treatment, statistical analysis demonstrated that the
effects of both losartan and amlodipine treatment were
significantly different in terms of controlling M/L and CTGF
and TGF-b expression of resistance arteries from hyper-
tensive patients. Also, an opposite effect on ET-1 production
was observed in losartan and amlodipine groups. Losartan
did not change ET-1 expression, while amlodipine tended to
increase the production of this potent vasoconstrictor
implicated in remodeling. Previous studies have demon-
strated an opposite mechanism of action between losartan
and amlodipine on renal hemodynamics and on profibro-
genic cytokines, which could be responsible for their
contrasting effects in the regression of fibrosis. In renal
transplant patients with chronic allograft nephropathy, In˜igo
et al.32 have demonstrated that treatment with losartan
significantly decreased TGF-b plasma levels; meanwhile no
significant changes were observed with amlodipine, despite
similar control of BP. These different effects of losartan and
amlodipine on TGF-b could partially explain the differences
in ET-1, since in vitro and in vivo studies have demonstrated
that AngII and TGF-b are important stimuli for the synthesis
of ET-1.18,33 Thus, reduction in arterial pressure in systemic
HTA will not promote the regression of established fibrosis,
and active degradation of collagen by proteolytic enzymes
is required. Losartan can revert renal vascular fibrosis by
shifting the balance toward collagen degradation through the
inhibition of the effects of Ang II and TGF-b on collagen
synthesis and the activation of matrix metalloproteinase-2
(MMP-2), a potent gelatinase.34 As opposed to losartan,
amlodipine has been reported to decrease MMP-2 expres-
sion.35 Of note, inhibition of vascular MMP-2 in rat
mesenteric arteries resulted in an increased endothelin-1
generation.36 Unfortunately, the experimental design of our
study did not allow conclusions about the implications of
metalloproteinases in the regression of M/L observed in
losartan-treated patients.
In contrast to our findings, Schiffrin et al.25 reported that
hypertensive patients treated with amlodipine during 1 year
exhibited a significant improvement in small artery structure.
Although caution must be taken in the interpretation of
results from studies with small number of patients, some
differences exist between both studies. In the study of
Schiffrin et al., patients had been previously treated with
atenolol, and seven to ten patients receiving amlodipine
needed diuretics to achieve the BP goal. In the present study,
although we did not observe an influence of the diuretic
treatment on the structure of resistance arteries (confirming
previous studies from other groups12,15,25), none of our
hypertensive patients had previously treated with antihyper-
tensive drugs. In addition, we cannot exclude that the
discrepancy in the results could be due to differences in the
diameter of the studied arteries (60–80 vs 4200 mm), since
several reports have demonstrated that small arteries of
different sizes may present different kinds of structural and
mechanical alterations.2 Further studies are required to
address this issue.
The presence of structural alterations in the microcircula-
tion is considered an important mechanism of organ
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damage.2,3 Structural changes in the preglomerular vascu-
lature may have a particular significance in the development
and maintenance of hypertension, because the kidney
receives 25% of the cardiac output and is a key long-term
regulator of arterial pressure.1 It has been reported that
reduction in intrarenal vessel diameter may be prohyperten-
sive by mimicking the hemodynamic effects of main renal
artery stenosis. Thus, previous studies have reported a
prognostic significance of the M/L of small arteries in a
high-risk population.8,37 Whether the beneficial effect of
losartan on subcutaneous resistance arteries will correlate
with similar effects in other vascular beds remains to be
demonstrated.
In conclusion, the administration of a losartan improved
the structural abnormalities and prevented significantly
increments in CTGF and TGF-b expression of small arteries
in patients with mild to moderate essential HTA. None of
these beneficial effects was found in a parallel group of
hypertensive patients treated with amlodipine, despite similar
BP lowering. These data demonstrate, for the first time, that
CTGF may play an important role in the mechanisms
underlying the structural alterations of small arteries from
patients with essential HTA, and suggest a new mechanism by
which losartan can offer better cardiovascular protection
beyond BP reduction.
MATERIALS AND METHODS
Patients
The protocol was approved by the Ethics Committee of the Hospital
La Paz (Madrid). Subjects aged 25–65 years were recruited from the
Division of Hypertension of Internal Medicine. Patients had been
recently diagnosed of essential HTA and had never received
antihypertensive therapy. Recruited hypertensive patients had
recumbent diastolic BP 490 mmHg on at least three occasions.
Exclusion criteria included smoking more than five cigarettes per
day, abnormal fasting blood glucose level, serum creatinine
concentration 4150 mmol/l and the presence of other systemic
diseases. In total, 50 hypertensive patients complied with the
inclusion/exclusion criteria and were asked to participate in the
study. Also, 28 patients refused to be included.
Nine normotensive subjects (systolic and diastolic BP below 140
and 85 mmHg) were recruited simultaneously with the patients;
otherwise, there were no significant differences from hyper-
tensive patients in age, smoking status, serum creatinine, and
fasting glucose levels. Normotensive subjects and patients with
essential HTA provided written informed consent to participate
in the study.
Study design
In all, 22 never-treated hypertensive patients were randomly
assigned to receive 50 mg losartan or 5 mg amlodipine. If diastolic
BP was 490 mmHg after 1 month, the dose of drugs was doubled.
After 1 and 2 months, 12.5 and 25 mg of hydrochlorothiazide,
respectively, were added in both groups if needed. After 4 months,
concomitant add-on medication with doxazosin was allowed in
both groups.
Superficial subcutaneous fat biopsies from hypertensive patients
were obtained on two occasions: at the beginning of the study
(basal) and after 1 year of treatment. In normotensive subjects,
biopsies were obtained only once.
Vascular Morphometry
Vascular histopathological studies were performed in paraffin-
embedded sections 4mm thick. Arterial cross sections were stained
with orcein to highlight the elastic tissue, and counterstained with
Van Gieson picrofuchsin to visualize the collagen fibers. Measure-
ments were made with computer-assisted image analysis software
(Optimas 6.5, Media Cybernetics, Inc., Silver Spring, MD). The
following parameters were measured: external diameter, lumen (L),
media thickness (M), and media cross-sectional area. All parameters,
but the MSCA, were measured at the widest part of the shortest
diameter in every given vessel section, which represents a point of a
perfect (circular) arterial cross section. The M/L ratio was calculated
as 100M/L. Morphological results from 3–5 different arteries in
each patient were averaged to provide one mean measurement per
subject. A pathologist, unaware of the patient group to which the
specimen belonged, performed the study of the arteries.
Immunohistochemistry
Immunolocalization of CTGF, TGF-b, collagen III, collagen IV, and
endothelin-1 (ET-1) proteins was performed in paraffin-embedded
tissues. For the immunohistochemistry of ET-1, the slides were
washed and incubated in trypsin (0.1% trypsin/0.1% CaCl2 w/v) to
expose the antigenic sites. Sections were incubated with one of the
following antibodies: a polyclonal anti-CTGF antibody (1:100;
Abcam Ltd, Cambridge, UK), a polyclonal anti-TGF-b antibody
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA), a polyclonal
anti-collagen III antibody (1:50; Calbiochem, Merck Biosciences Ltd,
Nottingham, UK), a polyclonal anti-collagen IV antibody (1:50;
DAKO A/S, Glostrup, Denmark), or a rabbit polyclonal anti-ET-1
antibody (1:800; Peninsula Laboratories Europe Ltd, Merseyside,
UK) overnight at 41C in a humid atmosphere. Negative control
slides were treated with diluted normal rabbit serum. The sites of
peroxidase activity were visualized with 0.05% 3,30-diaminobenzi-
dine (DAKO A/S). Sections were counterstained with Mayer’s
hematoxylin (Sigma, St Louis, MO).
The intensity of CTGF, TGF-b, collagen III, collagen IV, and ET-1
staining was evaluated by using specialized computer-assisted image
analysis software (Optimas 6.5, Media Cybernetics). Software
designed for immunostaining analyses enabled the operator to set
density threshold values by averaging several arteries on the negative
control tissues. Background subtraction was then performed
automatically on every artery studied. In each patient, 3–5 different
arteries were assessed for positive brown staining. The results are
expressed as the labeling index, which represents the percentage
of the cross-sectional area positively stained. A pathologist
blinded to the group to which the vessels belonged performed the
study of arteries.
Statistical analysis
Results are presented as mean7s.e.m. For comparison of normo-
tensive and hypertensive results prior to treatment, the data of the
losartan and the amlodipine groups were pooled, and differences
were tested by a grouped t-test. The effect of treatment in each
treated group was tested with a two-tailed, paired t-test on changes
in values seen in each patient (before and after 1 year of treatment).
Differences in the effects of treatments were tested with a two-tailed,
unpaired t-test on the changes seen in each group at the end of the
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study. Correlations were obtained using the Spearman’s rank
correlation method. A value of Po0.05 was considered statistically
significant.
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